<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01492374</url>
  </required_header>
  <id_info>
    <org_study_id>CN167-003</org_study_id>
    <secondary_id>2011-004065-33</secondary_id>
    <nct_id>NCT01492374</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate safety and the pharmacodynamic effects of BMS-241027
      on cerebrospinal fluid (CSF) Tau, connectivity magnetic resonance imaging (MRI), and
      computerized cognitive tests in mild Alzheimer's disease (AD) subjects, following 9 weekly
      intravenous (IV) infusions of BMS-241027
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessments: based on frequency of Serious Adverse Events (SAEs), frequency of Adverse events (AEs), discontinuation due to AEs and dose reduction</measure>
    <time_frame>Within the first 70 day after first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biomarker Measures: CSF levels of Tau N-terminal domain fragments</measure>
    <time_frame>Within the first 70 day after first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of BMS-241027 on CSF levels of the mid-domain Tau fragment</measure>
    <time_frame>Within the first 70 days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of BMS-241027 on cognitive performance using computerized cognitive tests</measure>
    <time_frame>Weeks 3, 6 and 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of BMS-241027 on connectivity MRI</measure>
    <time_frame>Within the first 70 days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal observed plasma concentration (Cmax) of BMS-241027 in subjects with mild Alzheimer's disease</measure>
    <time_frame>Weeks 1, 4, and 9</time_frame>
    <description>Intensive pharmacokinetic parameter Cmax will be derived from subgroups of subjects at Week 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed plasma concentration at 24 hours post dose (C24) of BMS-241027 in subjects with mild Alzheimer's disease</measure>
    <time_frame>Weeks 1, 4, and 9</time_frame>
    <description>Intensive pharmacokinetic parameter C24 will be derived from subgroups of subjects at Week 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximal observed plasma concentration (Tmax) of BMS-241027 in subjects with mild Alzheimer's disease</measure>
    <time_frame>Weeks 1, 4, and 9</time_frame>
    <description>Intensive pharmacokinetic parameter Tmax will be derived from subgroups of subjects at Week 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-241027 in subjects with mild Alzheimer's disease</measure>
    <time_frame>Weeks 1, 4, and 9</time_frame>
    <description>Intensive pharmacokinetic parameter AUC(TAU) will be derived from subgroups of subjects at Week 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments: based on vital sign measurements, ECGs and clinical laboratory tests</measure>
    <time_frame>Within the first 70 day after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of BMS-241027 on CSF levels of neurofilaments</measure>
    <time_frame>Within the first 70 days after first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1: BMS-241027 (0.003 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: BMS-241027 (0.01 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: BMS-241027 (0.03 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Placebo matching BMS-241027</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-241027</intervention_name>
    <description>Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks</description>
    <arm_group_label>Arm 1: BMS-241027 (0.003 mg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-241027</intervention_name>
    <description>Intravenous (IV), 0.01 mg/kg, Once Weekly, 9 weeks</description>
    <arm_group_label>Arm 2: BMS-241027 (0.01 mg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-241027</intervention_name>
    <description>Intravenous (IV), 0.03 mg/kg, Once Weekly, 9 weeks</description>
    <arm_group_label>Arm 3: BMS-241027 (0.03 mg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching BMS-241027</intervention_name>
    <description>Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks</description>
    <arm_group_label>Arm 4: Placebo matching BMS-241027</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild AD Subjects meeting National Institute of Neurological Disorders and Stroke -
             Alzheimer's Disease Related Disorders Association(NINCDS-ADRDA) and Diagnostic and
             Statistical Manual of Mental Disorders-Forth Edition, Text Revision (DSM-IV-TR)
             criteria

          -  Mini-Mental State Exam (MMSE) Score between 20 &amp; 26 (inclusive)

          -  CSF consistent with AD pathology

          -  Screening brain MRI - normal - commensurate with age or demonstrate atrophy consistent
             with AD diagnosis (dx); reveal no more than mild white matter disease; up to 2 lacunar
             infarcts acceptable except in anterior thalamus, genu of internal capsule or basal
             forebrain; reveal no cortical infarcts; reveal no more than 4 microbleeds; reveal no
             focal asymmetric lobar atrophy or other findings suggesting primary cause of dementia
             is attributed to a cause other than AD; reveal no macrohemorrhages (&gt;10 mm)

          -  Subjects must have reliable study partners

          -  Men and Women of Non Child Bearing Potentia (WONCBP), ages 50-90 years

        Exclusion Criteria:

          -  Subjects with any other medical condition other than mild AD that could explain
             subjects' memory or cognitive deficits

          -  Subjects diagnosed with moderate or severe AD per DSM-IV criteria

          -  Subjects with a history (hx) of stroke

          -  Subjects with a hx of GI illnesses

          -  Subjects with Vitamin B12 or folate deficiency

          -  Subjects with any unstable cardiovascular (CV), pulmonary, Gastrointestinal (GI) or
             hepatic disease within 30 days prior to screening

          -  Subjects with active liver dx or history of hepatic intolerance

          -  Subjects with a Geriatric Depression Scale score of â‰¥ 6 at screening

          -  Subjects treated for or have had a diagnosis of schizophrenia

          -  Subjects treated for or have had a diagnosis of bipolar disease within 3 years prior
             to screening

          -  Subjects with a history of generalized peripheral neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials Llc</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsf Memory And Aging Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpine Clinical Research Center, Inc.</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Neurologists Of Southern Connecticut, P.C.</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, Llc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Neurological Center Advanced Research Consultants</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Neurosciences Institute Clinical Research</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham And Women'S Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center, Llc</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Of The University Of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Memory Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifetree Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse</city>
        <state>Cedex 9</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2011</study_first_submitted>
  <study_first_submitted_qc>December 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2011</study_first_posted>
  <last_update_submitted>July 23, 2014</last_update_submitted>
  <last_update_submitted_qc>July 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

